The present invention relates to a method of treating acute lymphoblastic leukemia in a patient in need thereof comprising administering to the […]
Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in […]
Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML). To address this issue, the inventors generated a syngeneic […]
The present invention relates to lipid nanoparticle loaded with antitumoral agent andfunctionnalized to target immosuppressive cells. Inventors […]
Adult T-cell leukemia/lymphoma (ATL) is an aggressive proliferation of mature activated CD4+ T cells associated with the human T-cell lymphotropic […]
The invention relates to a CDC25A phosphatase inhibitor for use in the treatment of drug resistant cancer or for use in the prevention of tumor […]
Natural killer (NK) cells are innate cytotoxic lymphoid cells (ILCs) involved in the killing of infected and tumor cells. Several NK cell subsets have […]
The present invention relates to a method for discontinuing a treatment with a TKI by determining the number and/or frequency of innate CD8(+) T-cells […]
Deciphering the impact of metabolic intervention on response to anticancer therapy represents a path toward improved clinical responses. Here, the […]